GI
NPCE icon

GAMMA Investing’s Neuropace NPCE Stock Holding History

GAMMA Investing’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9
Closed -$139 – 4198
2025
Q4 		$139 Buy
+9
New +$120 ﹤0.01% 4040
2025
Q3 		– Sell
-402
Closed -$4.48K – 3897
2025
Q2 		$4.48K Buy
402
+50
+14% +$625 ﹤0.01% 3168
2025
Q1 		$4.33K Buy
+352
New +$4.41K ﹤0.01% 3140

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

GAMMA Investing's NPCE Position: Q1 2026 in Review

GAMMA Investing sold out of Neuropace (NPCE) in Q1 2026, closing a stake of 9 shares — an estimated $139 sold.

GAMMA Investing first reported a position in NPCE in Q1 2025 and held it in 3 quarters. The position peaked at $4.48K in Q2 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • GAMMA Investing reported no remaining Neuropace position as of Q1 2026 after selling out during the quarter.
  • GAMMA Investing sold 9 Neuropace shares in Q1 2026, an estimated $139.
  • GAMMA Investing first reported a position in Neuropace in Q1 2025 and held it in 3 quarters.
  • GAMMA Investing's Neuropace position peaked at $4.48K in Q2 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on GAMMA Investing's 13F filing for Q1 2026, filed 6 Apr 2026.